Quote from one diabetic article: "...research suggests that inhaled insulin is preferred to subcutaneous insulin. Most (85%) patients who received an inhaled insulin during the main phase of a clinical trial chose to continue doing so during the open-label extension phase, and 75% of patients using subcutaneous insulin during the parallel group phase chose to switch to the inhaled insulin.”
The elderly, those who are just simply too worried about possible unforeseen long-term negative effects, of course the smokers, and those with COPD, - am thinking 50% market capture somewhere around 2018/2019........absolutely huge revenue in time. Surveys indicate somewhere near 25% US market capture within first 12 to 18 months alone, of course assuming a reasonable FDA label. Very sad when such a treatment emerges and the major 'fear' is that FDA's reputation for corruption and obstructionism will torpedo it. I think it is a given that EMEA approves, and the FDA knows it as well.
I think we will all be very happy with the the transition as all ages will make the switch. The elderly will like it from the ease of use. Much easier for them to take a hit off the ole pipe rather than blasting themselves with a needle.
Tay, I take no offense in you asking for the article reference. Always feel free to ask me such things.
Exact quote comes from the article "Never Trust the Street, The Afrezza Paradigm Shift". The information in that article regarding the numbers quoted came from the a study, whose results were published in an article titled, “Effect of Technosphere Inhaled Insulin on Quality of Life and Treatment Satisfaction” (Mark Peyrot, Richard R. Rubin. Diabetes Technology & Therapeutics. January 2010, 12(1): 49-55.
Think about it. What are T1 diabetics alternatives? Needle or oral maybe? I would take the huff no matter how painless the needle was. No contest, but that's me, I'm used to being on the back side of the needle if you know what I mean. The sticker not the stickee.
This abstract supports your conclusion...Thanks pfg_01
OBJECTIVE—We sought to compare and evaluate the impact of inhaled versus injected insulin on potential mediators of patient acceptance of insulin therapy while maintaining comparable A1C levels.
RESEARCH DESIGN AND METHODS—During a noninferiority efficacy trial conducted in 40 centers in the U.S., we surveyed treatment satisfaction, quality of life, and adherence barriers at weeks −4, −1, 6, 12, 20, and 24 in adolescents aged 12–17 years and adults with type 1 diabetes who received premeal regular plus twice-daily NPH insulin during a 4-week run-in; then, subjects were randomized to premeal inhaled human insulin plus twice-daily NPH (adults, n = 102; adolescents, n = 60) (inhaled) or remaining on run-in therapy (n = 105 and 60, respectively) (subcutaneous injection).
RESULTS—Overall treatment satisfaction (0–100) increased by 13.2 ± 1.1 units for inhaled insulin (baseline = 63.3 ± 1.2) compared with 1.7 ± 0.8 for subcutaneous insulin injection (baseline = 64.1 ± 1.2, P
This is great Kevin. Thank you for the additional supporting info. As a group on this board, we continue to find more and more overwhelming evidence that supports what a blockbuster Afrezza is going to be.
85% of patients in one clinical trial are all "diabetics". Laughable. How many total patients were in this trial? Quote the study and quote the number of patients. More importantly, who paid for the study? MNKD? LOL.
If you want to know how real, non-biased T1's feel on the subject, you can easily go to TuDiabetes, SweetLife, Diabetes Mine, SixUntilMe, D life, etc or any other real diabetes blogs to get your answer. The vast majority (probably well over 90%) of T1's who regularly inject insulin have no problem with needles.
Do some want a better treatment option? Yes, of course. But needles aren't necessarily the problem.
You call me a "liar" and then post nonsense like this? You and Matt must have come from the same school of hiding the ball and preying on the naive.
I would agree with Rapp regarding people who have suffered from T1D for a long period of time, such as he has. I've read many articles written by T1Ds and there is definitely a skeptical mindset among them. When you have a chronic condition, you continuously hear "in the next five years ... things will get better because" this great invention is coming or that great invention.
Mainly what they want is a cure, not a treatment. Many believe that treatments are there to make people money and cures aren't discovered because they aren't marketable.
But there is a huge market for new T1Ds who are more open to new devices and to T2Ds who don't want to inject. There is no doubt that there is a huge fear of needles. I think we can all agree on that. So, I think there are many T2Ds who don't inject because they don't like the idea of injecting.
If you are a T1D, you have to inject. You can't say "I'm scared." If you are scared, you'll die. then you realize that the injections don't hurt so much and you get used to it. The longer you do it, the more you're okay with it and the more likely you are to be skeptical of other methods.
so, long-term T1Ds, like Rapp, will be a hard sell.
There definitely will be a decent percentage of long term diabetics that are comfortable with injecting themselves, and will be resistant to change. But as time goes on newly diagnosed patients will definitely favor inhaled over injection.
Sentiment: Strong Buy